

China's Simcere Zaiming signs \$1.5 B deal with Roche for SIM0660 global development

September 2, 2026 | News

SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology



Simcere Zaiming, a subsidiary of China-based Simcere Pharmaceutical Group, has entered into an exclusive global licensing agreement with Roche for the development and commercialisation of SIM0660, a tri-specific antibody targeting CD79a, CD19, and CD3, with therapeutic potential across B-cell-mediated diseases.

Under the terms of the agreement, Roche will acquire exclusive global rights to develop, manufacture, and commercialise SIM0660.

Simcere Zaiming is eligible to receive up to \$1.5 billion in total payments, including \$75 million in upfront. Simcere Zaiming is also eligible to receive tiered royalties of up to double digits on future net sales.

SIM0660 is a tri-specific antibody developed by Simcere Zaiming using its T-cell engager poly-specific antibody technology. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce potent T cell-mediated cytotoxicity while limiting cytokine release.

With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell mediated diseases, and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies. In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit.

To date, Simcere Pharmaceutical Group has completed six out-licensing transactions, with a potential aggregate total consideration exceeding \$6.1 billion.